GlassScriptPhysician profile
Kimberly R Mills
NPI 1407114168
$2,687.22
in general payments reported to CMS, 2019-2025
23 companies · $87.63 in 2025
The $87.63 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $291 · 2021: $206 · 2022: $416 · 2023: $645 · 2024: $647 · 2025: $87.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,379.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $601.70 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $348.21 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $277.16 | 2019-2022 | |
| Novo Nordisk INC | $224.08 | 2019-2025 | Wegovy |
| Pfizer INC. | $211.16 | 2019-2024 | |
| Exact Sciences Corporation | $204.63 | 2023-2024 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $146.59 | 2019-2023 | |
| Viiv Healthcare Company | $146.46 | 2024 | Apretude |
| Sanofi-Aventis U.S. LLC | $79.03 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $64.41 | 2023-2025 | Rexulti |
| Edwards Lifesciences Corporation | $52.58 | 2022-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Amgen INC. | $47.05 | 2024 | Repatha, Otezla |
| Axsome Therapeutics, INC. | $45.58 | 2024-2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.32 | 2022-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $36.83 | 2023-2024 | Trelegy Ellipta, Shingrix |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $35.97 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.40 | 2022 | |
| Astellas Pharma US INC | $20.11 | 2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $19.24 | 2021 | |
| Lilly USA, LLC | $16.73 | 2024 | Zepbound, Mounjaro |
| Renalytix Ai, INC. | $16.66 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.99 | 2019 | |
| Abbott Laboratories | $11.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Mills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.